These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17145955)

  • 1. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
    Pion M; Granelli-Piperno A; Mangeat B; Stalder R; Correa R; Steinman RM; Piguet V
    J Exp Med; 2006 Dec; 203(13):2887-93. PubMed ID: 17145955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    Rose KM; Marin M; Kozak SL; Kabat D
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.
    Stopak KS; Chiu YL; Kropp J; Grant RM; Greene WC
    J Biol Chem; 2007 Feb; 282(6):3539-46. PubMed ID: 17110377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Gag-virus-like particles inhibit HIV-1 replication in dendritic cells and T cells through IFN-α-dependent upregulation of APOBEC3G and 3F.
    Chang MO; Suzuki T; Yamamoto N; Watanabe M; Takaku H
    J Innate Immun; 2012; 4(5-6):579-90. PubMed ID: 22739040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
    Kozak SL; Marin M; Rose KM; Bystrom C; Kabat D
    J Biol Chem; 2006 Sep; 281(39):29105-19. PubMed ID: 16887808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of allogeneic in vitro stimulation and in vivo immunization on memory CD4(+) T-cell APOBEC3G expression and HIV-1 infectivity.
    Pido-Lopez J; Wang Y; Seidl T; Babaahmady K; Vaughan R; Lehner T
    Eur J Immunol; 2009 Jul; 39(7):1956-65. PubMed ID: 19585516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term passage of Vif-null HIV-1 in CD4
    Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
    Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.
    Amoêdo ND; Afonso AO; Cunha SM; Oliveira RH; Machado ES; Soares MA
    PLoS One; 2011; 6(8):e24118. PubMed ID: 21897871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
    Wang X; Dolan PT; Dang Y; Zheng YH
    J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
    Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of Alu retrotransposition by APOBEC3G.
    Hulme AE; Bogerd HP; Cullen BR; Moran JV
    Gene; 2007 Apr; 390(1-2):199-205. PubMed ID: 17079095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
    Soros VB; Yonemoto W; Greene WC
    PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.